Open access
Aug 2026
Comparison of Culture Systems for Mouse Living Myocardial Slices in Cardiac Fibrosis Research
Nora Kopse, G. Bonazza, A. Laimbacher et al.
· bioRxiv · 0 citations
We have 4 of 29 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Aug 2026
Dysferlin is a novel regulator of COMP-positive matrifibrocytes in heart failure
I. Kocherova, Muriel Giger, A. Laimbacher et al.
· bioRxiv · 0 citations
Open access
Aug 2026
The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models
Elafibranor mitigates TGF-β1-driven cardiac fibrosis by suppressing fibroblast activation and ECM remodelling while promoting adaptive metabolic, redox, and bioenergetic responses, supporting balanced PPAR-α/δ activation as a potential therapeutic strategy for cardiac fibrosis.
M. Paw, L. Minder, A. Laimbacher et al.
· bioRxiv · 0 citations
Open access
Aug 2026
Lanifibranor (IVA-337) - a pan-PPAR agonist suppresses TGF-β1-induced cardiac fibrosis and rescues cardiomyocyte function
Lanifibranor attenuates TGF-β1-driven cardiac fibrosis by combining antifibrotic effects with metabolic and functional improvements in human models.
M. Paw, L. Minder, A. Laimbacher et al.
· bioRxiv · 0 citations